NADINE BEAUGER

NADINE BEAUGER, Ph.D., MBA

Chief Executive Officer, IRICoR

 

T + 514 343.0315
F + 514 343.7780
nadine.beauger@umontreal.ca

 

Biography :

Since 2016, Dr. Nadine Beauger is Chief Executive Officer at the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR). Before this appointment, Dr. Beauger was Vice-President – Scientific Liaison (intellectual property, academia-industry relations) at the same organization that she joined in 2009. She was instrumental at building IRICoR’s project portfolio and related intellectual property (IP) activities. She led strategic IP portfolio management including a dedicated IP budget, building and implementing the strategy for portfolio of patent families (40) which have led to successful licensing agreements and partnerships with industry (multi-million$ in total deal value).

Dr. Beauger began her career as a Patent Consultant at Robic, a Montreal-based IP boutique, where she undertook drafting, prosecution and IP strategic management of biotechnology patent applications. She went on as Associate at VantagePoint Venture Partners, a leading California-headquartered venture capital firm with more than $4 billion under management. She led due diligence on investment opportunities in health sciences and monitored ten of the firm’s portfolio companies. Just prior to joining IRICoR, Dr. Beauger was Business Development Manager at Paladin Labs Inc, a top specialty pharmaceutical company based in Montreal.

She holds a Ph.D. in Biomedical Sciences (Hematology and Oncology), an M.Sc. in Cellular Biopathology from Université de Montréal and a B.Sc. in Anatomy from McGill University. She also holds an MBA degree from HEC Montréal (Excellence Studentship Award and Best Speaker Award). Dr. Beauger is a member of the Board at CHU Ste-Justine Foundation and a member of the Association of University Transfer Managers (AUTM).

She brings over 15 years of experience in technology assessment and transfer, venture capital, intellectual property and project portfolio management, due diligence, and clinical and biotechnological research with thorough experience in both the private and the academic sectors.